S-adenosyl methionine (SAMe) for depression in adults.

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Depression is a chronic, treatment-resistant illness with substantial economic impact.
• S-adenosyl methionine (SAMe), a naturally occurring compound, has demonstrated potential antidepressant efficacy.
• SAMe may represent a valuable addition to existing antidepressant treatments.

Purpose of the Study:

• To evaluate the efficacy of SAMe against placebo and established antidepressants in adults with depression.
• To assess SAMe's effectiveness as both monotherapy and adjunctive treatment.

Main Methods:

• Systematic review of randomized controlled trials comparing SAMe with placebo or antidepressants (imipramine, desipramine, escitalopram).
• Included trials involved 934 adults with major depression, using SAMe as monotherapy or add-on therapy to SSRIs.
• Data extraction and risk of bias assessment were performed independently by two authors.

Main Results:

• No strong evidence of difference in depressive symptom reduction between SAMe and placebo as monotherapy (very low quality evidence).
• SAMe showed similar efficacy to imipramine and escitalopram as monotherapy (low to very low quality evidence).
• Low quality evidence suggests SAMe may be superior to placebo as an add-on to SSRIs for depressive symptom reduction.

Conclusions:

• High-quality evidence is lacking, precluding firm conclusions on SAMe's efficacy for depression.
• Further large, high-quality randomized controlled trials are necessary to investigate SAMe's role in depression treatment.
• Future research should focus on methodological rigor and detailed adverse event reporting, particularly mania induction.